InvestSMART

Nexsen Limited (ASX: NXN) - Announcements

Current share price for NXN : $0.135 0.01 (8%)+

ASX company news and announcements for Nexsen Limited (NXN) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Nexsen Limited (NXN) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Nexsen Limited (NXN), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Nexsen Limited (NXN)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$13 Professor Shekhar Kumta appointed Executive Director 1 Oct 2026 8:14AM $0.125 $0.135 risen by 8%
$13 Reinstatement to Quotation 25 Sep 2026 9:40AM $0.165 $0.135 fallen by 18.18%
$13 Proposed FlashDx joint venture builds on CE-marked GBS test 25 Sep 2026 9:40AM $0.165 $0.135 fallen by 18.18%
$13 Suspension from Quotation 24 Sep 2026 10:22AM $0.165 $0.135 fallen by 18.18%
$13 Clear pathway defined to optimise StrepSure 24 Sep 2026 10:21AM $0.165 $0.135 fallen by 18.18%
$13 Trading Halt 22 Sep 2026 9:18AM $0.165 $0.135 fallen by 18.18%
$13 Director Interest Notices re Performance Rights 11 Sep 2026 9:29AM $0.180 $0.135 fallen by 25%
$13 Notification regarding unquoted securities - NXN 11 Sep 2026 9:19AM $0.180 $0.135 fallen by 25%
$13 Notification regarding unquoted securities - NXN 11 Sep 2026 9:13AM $0.180 $0.135 fallen by 25%
$13 Corporate Governance Statement and Appendix 4G 31 Aug 2026 7:55AM $0.200 $0.135 fallen by 32.50%
$13 Annual Report - FY 2026 31 Aug 2026 7:54AM $0.200 $0.135 fallen by 32.50%
$13 Quarterly Report - Q4 FY26 29 Jul 2026 8:33AM $0.270 $0.135 fallen by 50%
$13 Launch of Hong Kong facility & pipeline expansion 23 Jul 2026 9:07AM $0.295 $0.135 fallen by 54.24%
$13 Global Healthcare CEO Joins Nexsen Advisory Board 30 Jun 2026 8:43AM $0.240 $0.135 fallen by 43.75%
$13 $1.5m non-dilutive ARC funding for manufacturing 25 Jun 2026 8:36AM $0.225 $0.135 fallen by 40%
$13 Becoming a substantial holder 15 May 2026 5:11PM $0.225 $0.135 fallen by 40%
$13 Nexsen secures first hospital partner in Asia 13 May 2026 8:55AM $0.185 $0.135 fallen by 27.03%
$13 Nexsen and Universiti Malaya launch joint facility 4 May 2026 8:17AM $0.200 $0.135 fallen by 32.50%
$13 Quarterly Report - Q3 FY26 28 Apr 2026 9:35AM $0.215 $0.135 fallen by 37.21%
$13 QMS milestone achieved 7 Apr 2026 8:25AM $0.195 $0.135 fallen by 30.77%
$13 HK$6 million grant awarded to advance Asia-Pacific execution 31 Mar 2026 8:31AM $0.165 $0.135 fallen by 18.18%
$13 Nexsen accelerates global rollout for StrepSure 26 Mar 2026 8:17AM $0.165 $0.135 fallen by 18.18%
$13 FDA feedback derisks US approval pathway for StrepSure 23 Mar 2026 8:26AM $0.160 $0.135 fallen by 15.63%
$13 Half Yearly Report and Accounts 27 Feb 2026 9:11AM $0.160 $0.135 fallen by 15.63%
$13 Change in substantial holding - Nexsen 27 Feb 2026 9:03AM $0.160 $0.135 fallen by 15.63%

1 - 25 of 60 results

Page 1 of 3

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.